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It has been proposed that phyto-oestrogens protect against breast cancer. Lignans are the main class of phyto-oestrogens in Western
diets. We conducted a case–control study of breast cancer and serum levels of the main human lignan, enterolactone, nested within
a prospective cohort study, the New York University Women’s Health Study. Serum samples collected at enrollment and stored at
 801C were used. Among 14275 participants, 417 incident breast cancer cases were diagnosed a median of 5.1 years after
enrollment. Cohort members individually matched to the cases on age, menopausal status at enrollment, serum storage duration and,
if premenopausal, day of menstrual cycle were selected as controls. No difference in serum enterolactone was observed between
postmenopausal cases (median, 14.3nmoll
 1) and controls (14.5nmoll
 1), whereas premenopausal cases had higher levels
(13.9nmoll
 1) than their matched controls (10.9nmoll
 1, P-value¼0.01). In the latter group, the odds ratio for the highest vs the
lowest quintile of enterolactone was 1.7 (95% confidence interval (CI), 0.8–3.4; P-value for trend¼0.05) and after adjustment for
known risk factors for breast cancer was 1.6 (95% CI, 0.7–3.4; P-value for trend¼0.13). We observed a moderate positive
correlation between serum enterolactone and serum sex hormone-binding globulin in postmenopausal women (r¼0.29 in controls
(Po0.001) and r¼0.14 in cases (P¼0.04)), but no correlation with oestrogens or androgens. These results do not support a
protective role of circulating lignans, in the range of levels observed, in the development of breast cancer.
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It has been suggested that phyto-oestrogens protect against
hormone-dependent cancers, in particular breast cancer, through
their weak agonist/antagonist oestrogen properties as well as their
actions on oestrogen synthesis and bioavailability (Setchell et al,
1981; Adlercreutz et al, 1982; Adlercreutz, 1990; Rose, 1992). In
addition, phyto-oestrogens have been reported to have antioxidant
and antiproliferative properties which provide additional pathways
through which they may reduce cancer risk (Adlercreutz and
Mazur, 1997; Kurzer and Xu, 1997). The two main groups of phyto-
oestrogens found in humans, the isoflavonoids and the lignans, are
formed in the intestinal tract by transformation of plant precursors
(isoflavone glycosides and plant lignans) by the microflora. Soy
and soy products are the main sources of isoflavones, whereas
lignans are found in oilseeds, in particular flaxseed, whole-grain
products, nuts, berries, legumes, and some vegetables and fruits
(Thompson et al, 1991; Adlercreutz and Mazur, 1997; Mazur, 1998;
Horn-Ross et al, 2000).
A number of studies have focused on isoflavones and examined
the association of intake of soy or soy protein with breast cancer
risk, mostly in Asian populations (Peeters et al, 2003). Research on
the association between the dietary intake of specific phyto-
oestrogens, in particular lignans, and disease risk has been
hampered, though, by the paucity of data on the amount of these
compounds in individual foods, although the development of
appropriate databases is underway (Horn-Ross et al, 2000; Kiely
et al, 2003; Valsta et al, 2003). Dietary intake of foods known to be
rich in lignan precursors has been shown to correlate positively
with lignan plasma levels (Horner et al, 2002). Lignan intake,
assessed by a 24-h dietary recall, also correlated positively with
serum enterolactone (Kilkkinen et al, 2003), thus suggesting that
levels of circulating enterolactone may provide a useful alternative
approach to dietary questionnaires when assessing the effect of
lignans on disease risk.
The association between circulating levels of the main lignan
enterolactone and breast cancer risk was assessed in a case–
control study nested within the New York University (NYU)
Women’s Health Study, a prospective cohort study of cancer,
hormones, and environmental factors. The study focused exclu-
sively on enterolactone based on the results of a preliminary
study that examined the distribution and long-term reliability of
serum measurements of the two main lignans, enterolactone
and enterodiol, and of a number of isoflavonoid phyto-oestro-
gens. With the exception of enterolactone, phyto-oestrogen
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proportion of subjects, and the temporal reliability coefficients
were low, indicating that our cohort was not well suited to study
the effect of these compounds on disease risk (Zeleniuch-Jacquotte
et al, 1998). As some of the mechanisms of action suggested for a
protective effect of lignans are related to oestrogen synthesis and
bioavailability, we also examined the correlation of serum
enterolactone with circulating sex hormones and sex hormone-
binding globulin (SHBG) in the group of postmenopausal women
for whom these measurements were available (Zeleniuch-Jacquotte
et al, 2004).
MATERIALS AND METHODS
The NYU Women’s Health Study cohort
Between 1985 and 1991, the NYU Women’s Health Study enrolled
14275 healthy women aged 34–65 years at the Guttman Breast
Diagnostic Institute, a breast cancer screening centre in New York
City (Toniolo et al, 1991; Toniolo et al, 1995). Women who had
been pregnant or taken hormonal medications in the 6 months
preceding their visit were not eligible. At the time of enrollment,
women were classified as postmenopausal if they reported no
menstrual cycles in the previous 6 months, a total bilateral
oophorectomy, or a hysterectomy without total oophorectomy
prior to natural menopause and their age was 52 years or older. A
total of 7054 participants (49.4%) were postmenopausal. After
written informed consent was obtained, demographic, medical,
anthropometric and reproductive data were collected through self-
administered questionnaires. Dietary data were collected using a
semiquantitative food frequency questionnaire based on the Block
questionnaire used in NHANES II (Block et al, 1986, 1990). In
total, 30ml of non-fasting peripheral venous blood were drawn
prior to breast examination. After blood drawing, tubes were kept
covered at room temperature (21–251C) for 15min, then at 41C for
60min to allow clot retraction, and then centrifuged for 25min.
After centrifugation, serum samples were divided into 1ml
aliquots and immediately stored at  801C for subsequent
biochemical analyses. Up to 1991, women who returned for annual
breast cancer screening were invited to contribute additional blood
donations. Data on the use of oral contraceptives and hormone
replacement therapy were collected in follow-up questionnaires
mailed to participants in 1995 and in 1998.
Nested case–control study of breast cancer
The current study was based on an ongoing case–control study of
sex hormones and breast cancer. Cases were identified through
active follow-up of the cohort by mailed questionnaires approxi-
mately every 2–4 years and telephone interviews for nonrespon-
dents, as well as record linkage with state cancer registries in New
York, New Jersey and Florida, and with the US National Death
Index. A capture–recapture analysis estimated the ascertainment
rate in our cohort to be 95% (Kato et al, 1999). Only incident cases
(ie diagnosed at least 6 months after blood donation) of invasive
breast cancer were included. Medical and pathology reports were
requested to confirm the diagnosis.
Controls were selected at random among appropriate risk sets.
The risk set for a case consisted of all women who were alive and
free of cancer at the time of diagnosis of the case and who matched
the case on menopausal status at the time of enrollment, age at
entry (76 months), date of enrollment (73 months), and if
premenopausal, day of menstrual cycle at the time of blood
donation. For the present study of enterolactone and breast cancer,
one control was selected at random between the two controls (or
four for premenopausal women) selected for the study of sex
hormones in order to limit study costs. In addition, the following
exclusion criteria were applied to both cases and controls: (1) use
of antibiotics in the 4 weeks preceding blood donation because
such use has been shown to almost completely eliminate the
formation of enterolactone from plant precursors in the gut
(Borriello et al, 1985; Adlercreutz et al, 1986; Kilkkinen et al, 2002);
(2) diagnosis with other cancer or cardiovascular disease in order
to preserve the serum samples of these participants for the study of
these diseases.
Laboratory analyses
Enterolactone was measured by time-resolved fluoroimmunoassay
(Adlercreutz et al, 1998) with slight modifications (Stumpf et al,
2001). For the recovery calculation, 15ml of 3H-oestradiol
glucuronide (enterolactone glucuronide is not available) was
added to the tubes containing 200ml of plasma and equilibrated
for 30min at room temperature. Then, 200ml of acetate buffer 0.1 M
pH 5.0 containing 2Uml
 1 sulphatase and 0.2Uml
 1 b-glucur-
onidase were added. After mixing, the tubes were incubated
overnight at 371C. After hydrolysis, the free enterolactone was
extracted twice with 1.5ml of ethyl ether. The separation of the
phases was carried out by freezing the water phase. After
evaporation of the ether, 200ml of the TR-FIA assay buffer was
added and a 20ml aliquot taken for calculation of recovery and two
20ml aliquots used for the time resolved fluoroimmunoassay.
Samples from a case and her matched control were always assayed
in the same batch. The laboratory analyses were performed blind,
and all of the batches were analysed with two quality control
samples used throughout the whole procedure, and three samples
used for the immunoassay step only. Two samples from a common
pool that were labelled to preclude their identification were
interspersed every 11 matched sets to assess the laboratory
precision. The mean of the within-batch coefficient of variation
for the seven batches was 8.9%.
Statistical methods
Enterolactone measurements were log-transformed to reduce
departure from the normal distribution. To test for differences
in enterolactone levels (and other continuous variables) between
case and control subjects, we used a mixed-effects regression
model to take into account the matched design (Liang and Zeger,
1986). P-values to compare proportions between case and control
subjects were generated using the conditional logistic regression
model.
To compute odds ratios (ORs), serum measurements were
categorised into quintiles separately for pre- and postmenopausal
subjects, using the frequency distribution of the cases and the
controls combined. The data were analysed using conditional
logistic regression (Breslow and Day, 1980). Odds ratios were
computed relative to the lowest quintile. Likelihood ratio tests
were used to assess the significance of overall associations, linear
trends and deviations from linearity. Reported trend test P-values
correspond to enterolactone variables treated as ordered catego-
rical variables. Analyses were also performed on the continuous
variables. Analyses were conducted using the SAS Release 8.02 and
EGRET statistical packages. All P-values are two-sided.
RESULTS
A total of 461 incident breast cancer cases diagnosed prior to 1
January 1995 had been identified by the start date of the study, 1
September 1998. A total of 38 cases were excluded from the present
study for the following reasons: diagnosis of other cancer prior or
subsequent to diagnosis (n¼24), diagnosis of coronary heart
disease (n¼3), and use of antibiotics in the 4 weeks prior to study
enrollment (n¼11). Six additional cases were excluded because
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cases are included in this report. Nine participants became cases
after being selected as controls and are included both as cases and
controls in the appropriate matched sets (Robins et al., 1986).
Pathology reports were obtained for 349 cases (84%) and the
diagnoses of 59 additional cases (14%) were confirmed through
Tumour Registries.
Table 1 presents the characteristics of the study subjects by
menopausal status. The median age at blood donation was 44 years
in premenopausal women, and 59 years in postmenopausal
women, and the overall median lagtime between blood donation
and diagnosis was 5.1 years (range, 6 months to 9.5 years). Overall,
the proportion of nulliparous women was higher among cases
(31%) than among controls (25%, P¼0.05). Although no longer
statistically significant, this difference was observed in both pre-
and postmenopausal women. Among women premenopausal at
blood donation, cases tended to be older at first full-term
pregnancy (P¼0.08), reported more often a family history of
breast cancer (P¼0.001) and were less likely to have used
hormone replacement therapy than controls (P¼0.05). Among
postmenopausal women, cases tended to have a higher weight
(P¼0.01) and body mass index (P¼0.09) than controls.
Table 2 reports serum levels of enterolactone. Overall, levels
were higher in cases (median, 14.3nmoll
 1) than in controls
(12.8nmoll
 1, P¼0.04). When levels were examined according to
menopausal status, no difference was observed between post-
menopausal cases and controls, whereas premenopausal cases had
higher levels (median, 13.9nmoll
 1) than their matched controls
(10.9nmoll
 1, P¼0.01).
Table 3 reports ORs for breast cancer associated with quintiles
of enterolactone in premenopausal women. In the condi-
tional model controlling only for matching factors, a trend of
increasing risk with increasing level of enterolactone was observed
(P¼0.05). The OR was 1.7 (95% CI, 0.8–3.4) in the highest
quintile, which was slightly reduced to 1.6 (0.7–3.4) after adjusting
for the following known risk factors: age at menarche, family
history of breast cancer, parity, age at first full time pregnancy,
height and body mass index (P for trend¼0.13). Adjusting
further for use of oral contraceptives and hormone replacement
therapy did not materially affect the OR but reduced the number of
matched sets available for analysis to 139 (74% of total) and are
therefore not presented. Similar results were obtained when log-
transformed enterolactone was used on the continuous scale.
Table 4 shows the results among postmenopausal women. No
Table 1 Study subject characteristics by menopausal status at blood donation
a
Premenopausal women Postmenopausal women
Cases (n¼189) Controls (n¼189) Cases (n¼228) Controls (n¼228)
Age at blood donation, median (5–95th percentiles) 44.2 (36.6–51.7) 44.2 (36.3–52.0) 58.8 (52.5–64.8) 58.8 (52.5–65.0)
Age at diagnosis, median (5–95th percentiles) 49.1 (40.1–57.0) 64.2 (55.8–70.6)
Age at menarche, median (5–95th percentiles) 12 (10–15) 12 (10–16) 13 (10–15) 12 (10–15)
Nulliparous, n (%) 73 (39%) 58 (31%) 57 (25%) 47 (21%)
Age at first full-term pregnancy, median (5–95th percentiles)
b 25 (19–39) 24 (18–36) 25 (19–35) 24 (19–34)
History of breast cancer in first-degree relatives, n (%)
c 51 (27%) 25 (13%) 43 (19%) 51 (22%)
Total oophorectomy, n (%) 0 0 29 (13%) 25 (11%)
Ever used oral contraceptives, n (%) 91/164 (55%) 105/168 (63%) 44/198 (22%) 32/205 (16%)
Ever used hormone replacement therapy, n (%)
d 14/164 (9%) 26/168 (15%) 32/198 (16%) 30/205 (15%)
Height (cm), median (5–95th percentiles) 163 (152–175) 163 (152–173) 163 (152–173) 163 (152–170)
Weight (kg), median (5–95th percentiles)
e 61.3 (49.0–84.0) 61.3 (49.0–89.0) 68.1 (51.8–89.9) 63.6 (49.0–88.5)
Body mass index (kgm
 2), median (5–95th percentiles)
f 23.0 (18.5–31.3) 23.6 (19.0–32.5) 25.7 (20.2–33.0) 24.3 (19.7–32.5)
Energy intake (kcal), median (5–95th percentiles) 1319 (720–2475) 1359 (792–2510) 1427 (807–2723) 1491 (760–2549)
Percent energy from fat intake, median (5–95th percentiles) 43.0 (30.2–51.7) 42.2 (30.7–52.3) 38.8 (28.2–50.7) 39.2 (28.2–48.2)
Daily dietary fibre intake (g), median (5–95th percentiles) 11.2 (4.5–23.0) 10.9 (1.3–42.7) 14.5 (1.9–51.6) 14.3 (1.3–52.8)
aUnless specified, P-values were greater than 0.10.
bP¼0.08 in premenopausal women.
cP¼0.001 in premenopausal women.
dP¼0.05 in premenopausal women.
eP¼0.01 in
postmenopausal women.
fP¼0.09 in postmenopausal women.
Table 2 Descriptive statistics of serum enterolactone levels in cases and
controls
Enterolactone (nmoll
 1) Cases Controls P-value
a
All women (417 matched sets)
Arithmetic mean (s.d.) 18.5 (16.1) 17.2 (15.7) 0.04
Median (5–95th percentiles) 14.3 (2.0–49.6) 12.8 (1.3–51.1)
Premenopausal women (189
matched sets)
Mean (s.d.) 18.3 (17.0) 15.1 (14.2) 0.01
Median (5–95th percentiles) 13.9 (2.5–47.0) 10.9 (1.3–42.7)
Postmenopausal women (228
matched sets)
Mean (s.d.) 18.6 (15.4) 18.9 (16.7) 0.51
Median (5–95th percentiles) 14.5 (1.9–51.6) 14.3 (1.3–52.8)
aP-values are from the mixed-effects regression models, controlling for matching
factors.
Table 3 Odds ratios (95% confidence intervals) and logistic regression
coefficients (standard error) for breast cancer associated with premeno-
pausal serum levels of enterolactone
Cases, n
(%)
Controls,
n (%)
Simple odds
ratios (95%
CI)
a
Multivariate
odds ratios
(95% CI)
b
Serum enterolactone (nmoll
 1) quintiles
p4.98 32 (17%) 45 (24%) 1.0 1.0
4.99–9.95 34 (18%) 41 (22%) 1.3 (0.7–2.5) 1.3 (0.7–2.7)
9.96–16.04 37 (20%) 38 (20%) 1.4 (0.7–2.8) 1.3 (0.6–2.7)
16.05–24.09 44 (23%) 32 (17%) 1.9 (1.0–3.6) 1.7 (0.9–3.3)
X24.10 42 (22%) 33 (17%) 1.7 (0.8–3.4) 1.6 (0.7–3.4)
P-value for trend 0.05 0.13
ln (enterolactone),
b (s.e.) 0.252 (0.112) 0.218 (0.121)
P-value 0.02 0.07
aControlled for matching factors.
bControlled for matching factors and adjusted for
age at menarche, family history of breast cancer in mother or sisters, nulliparity and
age at first full-term pregnancy (o 23, 23–25, 26–29, X30, nulliparous), ln(height),
ln(body mass index).
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observed in this group.
There was no evidence of correlation between enterolactone and
oestrogens or androgens: all correlation coefficients were less than
0.10 (Table 5). However, we observed a positive correlation
between enterolactone and SHBG, which was stronger in controls
(0.29, Po0.001) than in cases (0.14, P¼0.04). This positive
correlation persisted after adjusting for body mass index, a strong
predictor of circulating SHBG: the partial correlation coefficients
were 0.26 (Po0.001) in controls and 0.13 in cases (P¼0.09).
DISCUSSION
Contrary to our hypothesis, we did not observe an inverse
association between serum levels of enterolactone and risk of
breast cancer. With 417 cases, the study had 80% power to detect
an odds ratio of 0.59 in the highest vs the lowest quartile, that is, a
41% reduction in risk. Although we cannot rule out an association
of smaller magnitude, we believe that the lack of inverse
association between enterolactone and breast cancer risk in our
study is not due to lack of statistical power because of the absence
of any trend among postmenopausal women and the marginally
significant positive trend observed among premenopausal women.
We also considered whether error in exposure measurement
could explain these results, since enterolactone was measured at a
single point in time whereas the true exposure of interest is long-
term average concentration of enterolactone. However, in a
preliminary study we have shown that, in our cohort subjects,
circulating enterolactone is fairly stable over a 2-year period of
time, as indicated by a reliability coefficient of 0.55 (Zeleniuch-
Jacquotte et al, 1998). In addition, because the study was based on
serum samples obtained prior to diagnosis of disease, the error in
measurement would be expected to be nondifferential with respect
to case–control status and therefore very unlikely to result in a
change of direction of the exposure–disease association in
premenopausal women (Kelsey et al, 1996).
Antibiotic use, through its action on the microflora of the gut,
greatly reduces circulating levels of enterolactone (Kilkkinen et al,
2002). Women who reported taking antibiotics in the 4 weeks
preceding blood donation were excluded, but recent data show that
serum enterolactone concentrations could be significantly lower
among subjects who use oral antimicrobials up to 12–16 months
before serum sampling, as compared to nonusers (Kilkkinen et al,
2002). Some women, both among cases and controls, with usually
high serum enterolactone levels may have been misclassified as
having low levels if they had taken antibiotics in the 1–16 months
prior to enrollment. However, it is again very unlikely that such
misclassification would result in a spurious positive association
among premenopausal women since we used prediagnostic sera.
Few studies have been published to date on the association
between biological levels of lignans and breast cancer risk. Three
studies reported on the urinary excretion of phyto-oestrogens
including lignans. In an individually matched case–control study
in Western Australia (144 cases), Ingram et al (1997) reported a
significant trend of reduced risk with increasing urinary excretion
levels of both equol and enterolactone. Results were not presented
separately for pre- and postmenopausal women, but the authors
noted that similar trends were observed within each group. A
population-based case–control study among Chinese women in
Shanghai (250 cases) reported a reduced risk with increasing
urinary excretion of total isoflavonoids and total lignans, which
was present in both pre- and postmenopausal women, although
stronger in premenopausal women (Dai et al, 2002). The only
prospective study that examined urinary phyto-oestrogen excre-
tion was a case–control study (88 cases and 268 controls) nested
within a cohort of postmenopausal Dutch women participating in a
breast cancer screening study (den Tonkelaar et al, 2001). Elevated
urinary genistein was weakly and nonsignificantly associated with
a risk reduction, whereas elevated urinary enterolactone was
weakly and nonsignificantly associated with increased risk.
Three studies have reported on the association of circulating
levels of lignans with breast cancer risk. A population-based case–
control study examined serum levels of enterolactone in 194 cases
and 208 controls in Eastern Finland (Pietinen et al, 2001). A
significant inverse association with risk was observed. Results were
similar in pre- and postmenopausal women. In a case–control
study nested in three population-based cohorts in northern
Sweden, there was no significant association of breast cancer risk
with serum enterolactone but further analyses showed a U-shaped
relationship with an increase in risk at both very low
(o5.5nmoll
 1), and very high (439.1nmoll
 1) concentrations
(Hulte ´n et al, 2002). Analyses stratifying by cohort showed that the
increase in risk with high levels of enterolactone was observed in
the two cohorts with only incident cases and a high proportion of
Table 4 Odds ratios (95% confidence intervals) and logistic regression coefficients (standard error) for breast cancer associated with postmenopausal
serum levels of enterolactone
Cases, n (%) Controls, n (%) Simple odds ratios (95% CI)
a Multivariate odds ratios (95% CI)
b
Serum enterolactone (nmoll
 1)
p5.40 43 (19%) 48 (21%) 1.0 1.0
5.41–11.41 45 (20%) 46 (20%) 1.1 (0.6–2.0) 1.3 (0.7–2.5)
11.42–19.30 48 (21%) 44 (19%) 1.2 (0.7–2.2) 1.2 (0.6–2.3)
19.31–29.07 45 (20%) 46 (20%) 1.1 (0.6–1.9) 1.3 (0.7–2.3)
X29.08 47 (21%) 44 (19%) 1.2 (0.7–2.3) 1.0 (0.5–2.1)
P-value for trend 0.58 0.95
ln (enterolactone), b (s.e.) 0.061 (0.092) 0.044 (0.101)
P-value 0.50 0.71
aControlled for matching factors.
bControlled for matching factors and adjusted for age at menarche, family history of breast cancer in mother or sisters, nulliparity and age at first
full-term pregnancy (o 23, 23–25, 26–29, X30, nulliparous), ln(height), ln(body mass index).
Table 5 Spearman correlation coefficients of serum enterolactone with
circulating sex hormones and SHBG in postmenopausal women
Cases (n¼188) Controls (n¼181)
Unadjusted Adjusted
a Unadjusted Adjusted
a
Oestradiol 0.04 0.07  0.09  0.07
Oestrone 0.06 0.09  0.06  0.05
Testosterone 0.12* 0.15** 0.02 0.03
Androstenedione  0.03  0.02  0.10  0.07
DHEAS 0.02 0.04  0.14*  0.12
SHBG 0.14** 0.13* 0.29*** 0.26***
aAdjusted for body mass index. * Po 0.10, ** Po 0.05, *** Po 0.001. All other P-
values 40.10.
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consisting mostly of older women (85% postmenopausal) from a
mammary screening project with mostly prevalent cases, a slight,
nonsignificant reduction in risk was observed with high plasma
enterolactone levels. Another nested case–control study, con-
ducted in Finland, showed no association, overall or within
menopausal groups (Kilkkinen et al, 2004).
It is noteworthy that all three retrospective case–control studies
(Ingram et al, 1997; Pietinen et al, 2001; Dai et al, 2002) reported
an inverse association of enterolactone with risk, whereas three of
the prospective studies reported no or weak positive associations
and one reported a U-shaped association with risk. It is unlikely
that the results from the case–control studies could be explained
by qualitative dietary modifications of the cases because one would
expect that women changing their diet in response to suspicion or
diagnosis of breast cancer would switch to ‘healthy diets’ usually
associated with increased enterolactone intake. However, whereas
controls contributed biological samples at their convenience,
collection of samples from cases occurred before admission to
hospital for surgery (Ingram et al, 1997), the morning of, or 1–2
days before surgery (Dai et al, 2002), or at a referral clinical
examination for breast symptom or suspected breast lump
(Pietinen et al, 2001). It is thus possible that cases, in these
stressful circumstances, reduced their overall intake of food,
including their intake of lignan-rich foods, resulting in lower
circulating or urinary enterolactone levels. In addition, in two of
the studies, it is possible that control subjects who agreed to
participate were self-selected for health-conscious behaviors,
including eating a healthy diet rich in lignan precursors: the
control participation rate was 72% in the Finnish study (Pietinen
et al, 2001) and 33% in the Australian study (Ingram et al, 1997).
Studies quantifying the intakes of specific phyto-oestrogens
using a food frequency questionnaire and a nutrient database may
shed additional light on the role of these compounds. Only one
such study has been published to date in relation to breast cancer.
The study was a case–control study in the San Francisco Bay Area
that included 1326 cases and 1657 controls from various non-Asian
ethnic backgrounds (Horn-Ross et al, 2001). Intake of total phyto-
oestrogens was not associated with altered risk, including in
analyses stratified by menopausal status or ethnic group. Analyses
by intake of seven specific phyto-oestrogenic compounds, includ-
ing lignans (matairesinol, secoisolariciresinol, and total lignans)
were also negative.
Enterolactone at plasma levels that could easily be achieved in
humans (400nmoll
 1) has been shown to inhibit both formation
and growth of breast tumours in rats (Saarinen et al, 2002). The
mechanisms that have been suggested for a protective role of
lignans against breast cancer include antioxidant effects (Kitts et al,
1999), competitive binding with oestrogen receptors (Martin et al,
1978; Adlercreutz et al, 1992) and oestrogen synthesis and
bioavailability (Adlercreutz, 1998). In cell culture systems,
enterolactone has been shown to be a moderate inhibitor of
aromatase, which is involved in the peripheral conversion of
androgens to oestrogens in postmenopausal women (Adlercreutz
et al, 1993; Wang et al, 1994). However, we did not observe an
association between circulating enterolactone and oestrogens in
our study. Lignans have also been shown to stimulate SHBG
synthesis in the liver (Adlercreutz et al, 1987, 1992). Adlercreutz
et al (1992) reported a significant positive correlation between the
urinary excretion of enterolactone and total lignans with plasma
SHBG in 30 postmenopausal women. In agreement with this study,
we observed a moderate positive correlation between serum
enterolactone and serum SHBG. Although it is therefore possible
that lignans increase SHBG levels, this effect did not translate into
a reduction in risk of breast cancer in our study.
Phyto-oestrogens could also affect the risk of breast cancer in
premenopausal women through changes in the menstrual cycle
length. Longer cycles have been shown to be associated with a
reduced risk (Olsson et al, 1983; LaVecchia et al, 1985), as would
be expected under the hypothesis that cumulative frequency of
ovulatory cycles is a primary determinant of risk (Henderson et al,
1985). Both daily supplementation with 10g of flaxseed, which is
very rich in lignans (Phipps et al, 1993), and a diet rich in soy
protein (Cassidy et al, 1994), a source of isoflavones, have been
reported to increase the length of the menstrual cycle, although not
in all studies (Wu et al, 2000; Maskarinec et al, 2002). However,
whereas this increase appeared to be due to an increase in
follicular phase length in the case of the soy protein diet (Cassidy
et al, 1994), flaxseed supplementation was associated with an
increase in luteal phase length (Phipps et al., 1993). As breast cell
division is low during the follicular phase but high during the
luteal phase with a peak at days 23–25 (Masters et al, 1977; Meyer,
1977; Ferguson and Anderson, 1981; Going et al, 1988; Potten et al,
1988), an increase in length of the luteal phase could contribute to
an increase in risk of breast cancer. Such a mechanism would be
consistent with our results as well as those of the den Tonkelaar
study (2001). However, these diet supplementation studies were
small in size and their results should be regarded as preliminary.
In addition, it is not clear that the generally moderate biological
levels of enterolactone in both our study and the den Tonkelaar
study would have a noticeable impact on menstrual cycle length.
Circulating levels of enterolactone following flaxseed supplemen-
tation are likely to be much higher than in our study (Morton et al,
1994; Tarpila et al, 2002).
In three of the prospective studies, an increase of breast cancer risk
was observed at high levels of enterolactone, although the results
were not significant in the Dutch study and only marginally
significant in our study. These results suggest a need for further
studies, both experimental and epidemiological, to better understand
the overall impact of lignans in general, and enterolactone in
particular, on the development of breast cancer. It also suggests
caution against large dietary intake of flaxseed or use of flaxseed
supplements for prevention: flaxseed is the oilseed with the richest
amount of lignan precursors, and flaxseed supplementation can more
than double serum enterolactone concentration (Tarpila et al, 2002).
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